About Alumis Inc. Common Stock
https://www.alumis.comAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
CEO
Martin Babler
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 74
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Oppenheimer
Outperform
Morgan Stanley
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
AYURMAYA CAPITAL MANAGEMENT COMPANY, LP
Shares:15.14M
Value:$368.5M
FORESITE CAPITAL MANAGEMENT V, LLC
Shares:5.78M
Value:$140.67M
SAMSARA BIOCAPITAL, LLC
Shares:4.8M
Value:$116.87M
Summary
Showing Top 3 of 133
About Alumis Inc. Common Stock
https://www.alumis.comAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.07M ▼ | $117.36M ▼ | $-110.75M ▼ | -5.36K% ▼ | $-1.06 ▼ | $-109.84M ▲ |
| Q2-2025 | $2.67M ▼ | $143.21M ▲ | $59.32M ▲ | 2.23K% ▲ | $0.78 ▲ | $-119.97M ▼ |
| Q1-2025 | $17.39M ▲ | $118.92M ▲ | $-98.96M ▼ | -569.11% ▼ | $-1.82 ▼ | $-100.69M ▼ |
| Q4-2024 | $0 | $97.8M ▼ | $-94.76M ▼ | 0% | $-1.74 ▼ | $-93.94M ▲ |
| Q3-2024 | $0 | $98.4M | $-93.12M | 0% | $-1.73 | $-97.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $377.72M ▼ | $488.01M ▼ | $103.24M ▼ | $384.77M ▼ |
| Q2-2025 | $486.32M ▲ | $610.92M ▲ | $125.6M ▲ | $485.33M ▲ |
| Q1-2025 | $208.75M ▼ | $261.3M ▼ | $92.98M ▲ | $168.31M ▼ |
| Q4-2024 | $288.26M ▼ | $340.99M ▼ | $80.89M ▲ | $260.1M ▼ |
| Q3-2024 | $361.87M | $412.56M | $64.17M | $348.39M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-110.75M ▼ | $-110.91M ▼ | $24.04M ▼ | $0 ▼ | $-86.87M ▼ | $-110.91M ▼ |
| Q2-2025 | $59.32M ▲ | $-106.35M ▼ | $129.4M ▲ | $749K ▲ | $23.58M ▲ | $-106.97M ▼ |
| Q1-2025 | $-98.96M ▼ | $-80.36M ▼ | $39.43M ▲ | $0 ▼ | $-40.98M ▲ | $-80.39M ▼ |
| Q4-2024 | $-94.76M ▼ | $-74.76M ▲ | $30.95M ▲ | $5K ▼ | $-43.89M ▼ | $-75.13M ▲ |
| Q3-2024 | $-93.12M | $-83.77M | $-93.19M | $235.15M | $58.2M | $-84.55M |
CEO
Martin Babler
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 74
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Oppenheimer
Outperform
Morgan Stanley
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
AYURMAYA CAPITAL MANAGEMENT COMPANY, LP
Shares:15.14M
Value:$368.5M
FORESITE CAPITAL MANAGEMENT V, LLC
Shares:5.78M
Value:$140.67M
SAMSARA BIOCAPITAL, LLC
Shares:4.8M
Value:$116.87M
Summary
Showing Top 3 of 133